InVera Medical Announces Promotion of Dr. Aisling O’Sullivan to Vice President for Quality Assurance and Regulatory Affairs

Aisling O'Sullivan Vice President of Quality Assurance and Regulatory Affairs with InVera Medical

InVera Medical, the developers of the InVera™ device – a less-invasive, effective, pain-free and faster minimally invasive endovenous medical device treatment for all chronic venous disease patients, proudly announce the promotion of Dr. Aisling O’Sullivan to the position of Vice President for Quality Assurance and Regulatory Affairs.

Aisling has been an invaluable asset to InVera Medical since joining the company in 2021. Her dedication, expertise, and commitment to ensuring the highest standards of quality and regulatory compliance have played a crucial role in the success and growth of the organisation.

In her new role, Aisling will lead the Quality Assurance and Regulatory Affairs teams, overseeing and enhancing processes to maintain and exceed industry standards. Her responsibilities will include developing and implementing strategies to ensure compliance with regulatory requirements, optimising quality management systems, and fostering a culture of continuous improvement throughout the organisation.

Commenting on the announcement, Stephen Cox, CEO, InVera Medical, stated, “We are thrilled to announce Aisling’s well-deserved promotion to Vice President for Quality Assurance and Regulatory Affairs. Her extensive experience and unwavering commitment to quality and compliance makes her the ideal leader for this critical role. We are confident that under her guidance, InVera Medical will continue to set the highest standards in the industry.”

With over 20 years’ experience navigating complex regulatory landscapes and implementing effective quality assurance measures, Aisling has led quality and regulatory teams, resulting in multiple new devices worldwide. Before joining InVera Medical, she held various positions at the National Standards Authority of Ireland, Omega Pharma, XBolt Orthopaedics, OrthoXel, Cook Medical, and RQM+. She holds a PhD in Microbiology from University College Cork, and a BSc Biotechnology from Dublin City University.

InVera Medical looks forward to continued success under Aisling’s leadership, reinforcing the company’s commitment to delivering innovative and high-quality healthcare solutions.

*Investigational device not for sale in US or any international markets.

For more information, please contact info@inveramedical.com

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/invera-medical

X: https://twitter.com/InVeraMedical

InVera Medical Launches Groundbreaking €4.6 million BioVAS DTIF Project: Pioneering Advances in Microvascular Vessel Intervention for Venous Leg Ulceration.

Disruptive Technologies Innovation Fund Government of Ireland Project Ireland 2040
Disruptive Technologies Innovation Fund Government of Ireland Project Ireland 2040

InVera Medical is thrilled to announce the official kick-off meeting for the BioVAS: Biological Micro-Surgical Vessel Advanced Closure System project, funded by the Disruptive Technology Innovation Fund (DTIF) Call 4 at InVera Medical HQ in ATU Innovation Hubs.

This pioneering €4.6 million consortium project, led by InVera Medical, will focus on the development of BioVAS – a microvascular vessel wall intervention specifically designed for treatment of venous leg ulceration. At its core the BioVAS project exemplifies industrial research, aiming to acquire new knowledge and skills that will significantly enhance the treatment of Venous Disease.

We’re honoured to collaborate with esteemed partners – Atlantic Technological University – MET Technology Gateway, University of Galway – NCLA – National Centre for Laser Applications, and ICS Medical Devices in this transformative initiative.

The Disruptive Technology Innovation Fund is a €500 million fund established under the National Development Plan (NDP) in 2018 by the Department of Enterprise, Trade and Employment with administrate support from Enterprise Ireland.
 
A sincere thank you to the Disruptive Technology Innovation Fund team for their invaluable support. Together with our consortium we are committed to making a lasting impact on Venous Leg Ulcer patient care.

Read more via LinkedIn: https://www.linkedin.com/posts/invera-medical_biovas-biovas-venousdisease-activity-7140319017910591488-3KOI?utm_source=share&utm_medium=member_desktop

For more information:

Consortium Lead: InVera Medical Email: info@inveramedical.com


Project Partners: Atlantic Technological University – MET Technology Gateway | University of Galway – NCLA – National Centre for Laser Applications | ICS Medical Devices

“Investigational device not for sale in US or any international markets.”